ViiV's long-acting HIV injectable Cabenuva preferred over Biktarvy by 90% of patients in PhIII trial - Endpoints News
endpts.comSubmitted by endpointsnews6292 in health
Most HIV patients in a Phase III study investigating ViiV Healthcare's long-acting injectable Cabenuva and Gilead Sciences' daily pill Biktarvy preferred the injection over the pill, citing a range of physical and emotional benefits. Patients also reported im…